BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 30822141)

  • 1. 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety.
    Davis AK; So S; Lancelotta R; Barsuglia JP; Griffiths RR
    Am J Drug Alcohol Abuse; 2019; 45(2):161-169. PubMed ID: 30822141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The epidemiology of 5-methoxy- N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption.
    Davis AK; Barsuglia JP; Lancelotta R; Grant RM; Renn E
    J Psychopharmacol; 2018 Jul; 32(7):779-792. PubMed ID: 29708042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms.
    Uthaug MV; Lancelotta R; van Oorsouw K; Kuypers KPC; Mason N; Rak J; Šuláková A; Jurok R; Maryška M; Kuchař M; Páleníček T; Riba J; Ramaekers JG
    Psychopharmacology (Berl); 2019 Sep; 236(9):2653-2666. PubMed ID: 30982127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of Benefit Enhancement Strategies among 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) Users: Associations with Mystical, Challenging, and Enduring Effects.
    Lancelotta RL; Davis AK
    J Psychoactive Drugs; 2020; 52(3):273-281. PubMed ID: 32148190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A case report SPECT study and theoretical rationale for the sequential administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorder.
    Barsuglia JP; Polanco M; Palmer R; Malcolm BJ; Kelmendi B; Calvey T
    Prog Brain Res; 2018; 242():121-158. PubMed ID: 30471678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical pharmacology and potential therapeutic applications of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT).
    Reckweg JT; Uthaug MV; Szabo A; Davis AK; Lancelotta R; Mason NL; Ramaekers JG
    J Neurochem; 2022 Jul; 162(1):128-146. PubMed ID: 35149998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A narrative synthesis of research with 5-MeO-DMT.
    Ermakova AO; Dunbar F; Rucker J; Johnson MW
    J Psychopharmacol; 2022 Mar; 36(3):273-294. PubMed ID: 34666554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "In vivo biosynthesis of N,N-dimethyltryptamine, 5-MeO-N,N-dimethyltryptamine, and bufotenine in E.coli".
    Friedberg LM; Sen AK; Nguyen Q; Tonucci GP; Hellwarth EB; Gibbons WJ; Jones JA
    Metab Eng; 2023 Jul; 78():61-71. PubMed ID: 37230161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase 1, Dose-Ranging Study to Assess Safety and Psychoactive Effects of a Vaporized 5-Methoxy-N, N-Dimethyltryptamine Formulation (GH001) in Healthy Volunteers.
    Reckweg J; Mason NL; van Leeuwen C; Toennes SW; Terwey TH; Ramaekers JG
    Front Pharmacol; 2021; 12():760671. PubMed ID: 34912222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential of 5-methoxy-N,N-dimethyltryptamine in the treatment of alcohol use disorder: A first look at therapeutic mechanisms of action.
    Tap SC
    Addict Biol; 2024 Apr; 29(4):e13386. PubMed ID: 38600715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Behavioral and pharmacokinetic interactions between monoamine oxidase inhibitors and the hallucinogen 5-methoxy-N,N-dimethyltryptamine.
    Halberstadt AL
    Pharmacol Biochem Behav; 2016 Apr; 143():1-10. PubMed ID: 26780349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Open-label study of consecutive ibogaine and 5-MeO-DMT assisted-therapy for trauma-exposed male Special Operations Forces Veterans: prospective data from a clinical program in Mexico.
    Davis AK; Xin Y; Sepeda N; Averill LA
    Am J Drug Alcohol Abuse; 2023 Sep; 49(5):587-596. PubMed ID: 37734158
    [No Abstract]   [Full Text] [Related]  

  • 13. Molecular Docking, MM-GBSA, and Molecular Dynamics Approach: 5-MeO-DMT Analogues as Potential Antidepressants.
    Kalirajan R; Rishabh K; Srikanth J; Niharika M; Preeya N; Rezaul I
    Arch Razi Inst; 2023 Oct; 78(5):1603-1614. PubMed ID: 38590677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The serotonergic hallucinogen 5-methoxy-N,N-dimethyltryptamine disrupts cortical activity in a regionally-selective manner via 5-HT(1A) and 5-HT(2A) receptors.
    Riga MS; Bortolozzi A; Campa L; Artigas F; Celada P
    Neuropharmacology; 2016 Feb; 101():370-8. PubMed ID: 26477571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of psychedelic tryptamine derivatives with a lipid bilayer.
    Zohairi F; Khandelia H; Hakami Zanjani AA
    Chem Phys Lipids; 2023 Mar; 251():105279. PubMed ID: 36627076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The paradox of 5-methoxy-N,N-dimethyltryptamine: an indoleamine hallucinogen that induces stimulus control via 5-HT1A receptors.
    Winter JC; Filipink RA; Timineri D; Helsley SE; Rabin RA
    Pharmacol Biochem Behav; 2000 Jan; 65(1):75-82. PubMed ID: 10638639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reactivations after 5-methoxy-N,N-dimethyltryptamine use in naturalistic settings: An initial exploratory analysis of the phenomenon's predictors and its emotional valence.
    Ortiz Bernal AM; Raison CL; Lancelotta RL; Davis AK
    Front Psychiatry; 2022; 13():1049643. PubMed ID: 36523876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions.
    Shen HW; Jiang XL; Winter JC; Yu AM
    Curr Drug Metab; 2010 Oct; 11(8):659-66. PubMed ID: 20942780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-
    Rucker JJ; Roberts C; Seynaeve M; Young AH; Suttle B; Yamamoto T; Ermakova AO; Dunbar F; Wiegand F
    J Psychopharmacol; 2024 Apr; ():2698811241246857. PubMed ID: 38616411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensity of Mystical Experiences Occasioned by 5-MeO-DMT and Comparison With a Prior Psilocybin Study.
    Barsuglia J; Davis AK; Palmer R; Lancelotta R; Windham-Herman AM; Peterson K; Polanco M; Grant R; Griffiths RR
    Front Psychol; 2018; 9():2459. PubMed ID: 30574112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.